The Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients With Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data
Article in Turkish Journal of Hematology (May 2023)
The most recent citing publications are shown below. View all 2 publications that cite this research output on Dimensions.
Epoetin alfa-epbx: a new entrant into a crowded market. a historical review of the role of erythropoietin stimulating agents and the development of the first epoetin biosimilar in the United States
Article in Expert Review of Clinical Pharmacology (December 2020)